Actavis and Pfizer settle Celebrex litigation

Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Pfizer expects $1.9bn loss due to patent expirations

31 July 2018 US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.

Big Pharma

Pfizer drops Xeljanz patent suits

20 April 2021 Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.

Americas

Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent

16 November 2021 Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.

More on this story

Americas

Pfizer expects $1.9bn loss due to patent expirations

31 July 2018 US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.

Big Pharma

Pfizer drops Xeljanz patent suits

20 April 2021 Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.

Americas

Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent

16 November 2021 Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.

More on this story

Americas

Pfizer expects $1.9bn loss due to patent expirations

31 July 2018 US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.

Big Pharma

Pfizer drops Xeljanz patent suits

20 April 2021 Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.

Americas

Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent

16 November 2021 Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

Actavis and Pfizer settle Celebrex litigation

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features